Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print June 20, 2007, doi:10.1212/01.wnl.0000268695.63392.10)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Italian Translation
Right arrow All Versions of this Article:
01.wnl.0000268695.63392.10v1
69/4/342    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ravina, B.
Right arrow Articles by Elm, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ravina, B.
Right arrow Articles by Elm, J.
Received January 15, 2007
Accepted April 19, 2007

The impact of depressive symptoms in early Parkinson disease

B. Ravina MD, MSCE*, R. Camicioli MD, P. G. Como PhD, L. Marsh MD, J. Jankovic MD, D. Weintraub MD, and J. Elm MA

From the Department of Neurology (B.R., P.G.C.), University of Rochester School of Medicine and Dentistry, NY; Department of Neurology (R.C.), University of Alberta, Edmonton, Canada; Departments of Psychiatry and Neurology (L.M.), Johns Hopkins University, Baltimore, MD; Department of Neurology (J.J.), Baylor University, Houston, TX; Departments of Psychiatry and Neurology (D.W.), University of Pennsylvania, Philadelphia; and Department of Biostatistics (J.E.), Medical University of South Carolina, Charleston.


* To whom correspondence should be addressed. E-mail: Bernard.ravina{at}ctcc.rochester.edu.

Abstract Background: Depressive disorders may affect up to 50% of patients with Parkinson disease (PD) and are associated with increased disability and reduced quality of life. No previous study has systematically examined the impact of depressive symptoms in early, untreated PD. Methods: We administered the 15-item Geriatric Depression Scale (GDS-15) as part of two NIH-sponsored phase II clinical trials in PD, enrolling 413 early, untreated PD subjects. We used linear mixed models to examine the relationship of depressive symptoms, measured by the GDS-15, with motor function and activities of daily living (ADLs), as measured by the Unified PD Rating Scale (UPDRS). A time-dependent Cox model was used to examine the effect of demographic and clinical outcome measures as predictors of investigator-determined time to need for symptomatic therapy for PD. Results: A total of 114 (27.6%) subjects screened positive for depression during the average 14.6 months of follow-up. Forty percent of these subjects were neither treated with antidepressants nor referred for further psychiatric evaluation. Depression, as assessed by the GDS-15, was a significant predictor of more impairment in ADLs (p < 0.0001) and increased need for symptomatic therapy of PD (hazard ratio = 1.86; 95% CI 1.29, 2.68). Conclusions: Clinically important depressive symptoms are common in early Parkinson disease (PD), but are often not treated. Depressive symptoms are an important contributor to disability and the decision to start symptomatic therapy for motor-related impairment in early PD, highlighting the broad importance of identifying and treating depression in this population.




This article has been cited by other articles:


Home page
Arch NeurolHome page
S. A. Parashos, C. J. Swearingen, K. M. Biglan, I. Bodis-Wollner, G. S. Liang, G. W. Ross, B. C. Tilley, L. M. Shulman, and for the NET-PD Investigators
Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience
Arch Neurol, September 1, 2009; 66(9): 1099 - 1104.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
S. E Starkstein
Neuropsychiatric disorders in early untreated Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, August 1, 2009; 80(8): 830 - 830.
[Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
A Alonso, L A G. Rodriguez, G Logroscino, and M A Hernan
Use of antidepressants and the risk of Parkinson's disease: a prospective study
J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 671 - 674.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. Menza, R. D. Dobkin, H. Marin, M. H. Mark, M. Gara, S. Buyske, K. Bienfait, and A. Dicke
A controlled trial of antidepressants in patients with Parkinson disease and depression
Neurology, March 10, 2009; 72(10): 886 - 892.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
E. Tolosa, C. Gaig, J. Santamaria, and Y. Compta
Diagnosis and the premotor phase of Parkinson disease
Neurology, February 17, 2009; 72(7_Supplement_2): S12 - S20.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J Jankovic
Parkinson's disease: clinical features and diagnosis
J. Neurol. Neurosurg. Psychiatry, April 1, 2008; 79(4): 368 - 376.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. Karceski
Early Parkinson disease and depression
Neurology, July 24, 2007; 69(4): E2 - E3.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by AAN Enterprises, Inc.